BigHat successfully completed three project collaborations with Merck, triggering an undisclosed milestone payment. BigHat leveraged our integrated machine learning and high-speed wet lab to design and develop high-quality antibody candidates across diverse modalities, therapeutic areas (e.g., oncology, immunology), and protein engineering challenges. Merck is continuing evaluation of the BigHat sequences which  could unlock additional downstream milestone payments as the programs advance toward patients. 

*Merck Global Health Innovation Fund is also an investor in BigHat Biosciences.